Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
December 13, 2024
- Chuikyo Doctor Rep Positive on Industry’s Behavioral Changes after 2024 Reform
December 12, 2024
- JGA to Compile Interim Report on Generic Industry Revamp in May
December 12, 2024
- Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely
December 12, 2024
- Ex-Minister Takemi to Set Up Nonprofit to Bolster Pharma Innovation
December 11, 2024
- LDP Study Group Urges Health, Finance Ministers to Drop Off-Year Revisions
December 11, 2024
- PM Ishiba Elusive on Course of Off-Year Revisions: Diet Session
December 10, 2024
- Gene Therapies from Ferring, Ultragenyx in Line for Orphan Status, Moderna mRNA Drug Too
December 10, 2024
- PM Ishiba Takes Note of Opposition Party’s Plea for Scrapping Off-Year Revisions
December 9, 2024
- Japan PM Pledges to Seek Consensus in Diet on Off-Year Revisions
December 9, 2024
- Daiichi Sankyo’s TROP2 ADC, AZ’s COVID Antibody, Mpox Med in Line for Japan Approval
December 9, 2024
- Govt Unveils Draft Healthcare Strategy for 2025-2029 with Focus on Drug Innovation
December 6, 2024
- Xarelto, Equa Face Generic Debuts in Japan: December Listing
December 5, 2024
- LDP Lawmakers Continue Call to Abolish Off-Year Scheme
December 5, 2024
- Chuikyo Begins Debate on Scope of FY2025 Off-Year Drug Price Revisions
December 5, 2024
- DPP Submits Request to MOF for Scrapping Off-Year Revisions
December 5, 2024
- (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
- LDP Sees Growing Chorus of Opposition to Off-Year Revisions
December 4, 2024
- Japan Expected to Include Shingles Vaccines in NIP from FY2025
December 4, 2024
- Opposition DPP Leader Pledges to Go Full Throttle on Ending Off-Year Revisions
December 3, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…